Thelansis

Long QT Syndrome (LQTS) Market Outlook Thelansis’s “Long QT Syndrome (LQTS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Long QT Syndrome (LQTS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajec...

  Long QT Syndrome (LQTS) Market Outlook Thelansis’s “Long QT Syndrome (LQTS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Long QT Syndrome (LQTS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Long QT Syndrome (LQTS) Overview Long QT Syndrome (LQTS) could be a congenital or acquired heterogeneous syndrome that predisposes patients to arrhythmogenic syncope, seizures, and sudden cardiac death (SCD). Clinically, LQTS shows a lifelong asymptomatic state with no electrocardiographic (ECG) findings, and it is generally an asymptomatic state for life. Frequent and recurrent LQTS triggers emotional or physical stress and leads to...

  Long QT Syndrome (LQTS) could be a congenital or acquired heterogeneous syndrome that predisposes patients to arrhythmogenic syncope, seizures, and sudden cardiac death (SCD). Clinically, LQTS shows a lifelong asymptomatic state with no electrocardiographic (ECG) findings, and it is generally an asymptomatic state for life. Frequent and recurrent LQTS triggers emotional or physical stress and leads to SCD. The electrocardiographic QT interval represents the cardiac action potential's depolarization and repolarization phases. The interplay of several ion channels determines the action potential duration. Decreases in repolarizing outward K+ currents or increases in depolarizing inward sodium or calcium currents can prolong the QT interval, thus representing a pathophysiological substrate for LQTS. KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) are the most common LQTS genes, accounting for ≈90% of all genotype-positive cases. Heterozygous KCNQ1...